Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: TRANQUILITY BIODESIGN LLC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2024-02-21 to 2026-02-20
Current total value of award: $354996
Description: PHASE I THERAPEUTIC AWARD: A NOVEL ENGINEERED BACTERIAL ANTICANCER IMMUNOTHERAPY FOR MERKEL CELL CARCINOMA